Skip to main content
Top
Published in: Pediatric Cardiology 8/2016

01-12-2016 | Original Article

Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study

Authors: Giacomo Pongiglione, Alessandro Possidoni, Umberto di Luzio Paparatti, Anna Maria Costanzo, Giuliana Gualberti, Marco Bonvicini, Alessandro Rimini, Gabriella Agnoletti, Maria Pia Calabrò, Marco Pozzi, Roberto Tumbarello, Patrizia Salice, Patrizio Fiorini, Maria Giovanna Russo, Ornella Milanesi

Published in: Pediatric Cardiology | Issue 8/2016

Login to get access

Abstract

Children affected by hemodynamically significant congenital heart disease (HSCHD) experience severe respiratory complications that can increase the frequency of hospitalizations. The aim of the SINERGY study was to describe the incidence of respiratory diseases and to collect information on active and passive immunoprophylaxis in the first 2 years of life. In this retrospective, multicenter, and epidemiologic study, children with HSCHD were enrolled across 11 Italian sites. Children born between December 31, 2007, and December 31, 2012, were observed during their first 2 years of life. Data were collected through hospital database searches and parent interviews. Four hundred twenty children were enrolled: 51.7 % were female, 79.5 % were born full-term (≥37 weeks), and 77.6 % weighed >2500 g at birth. The most frequent heart defects were ventricular septal defect (23.1 %) and coarctation of the aorta (14.3 %). The incidence of respiratory diseases was 63.1 %. Frequent respiratory diseases not requiring hospitalization were upper respiratory tract infections (76.4 %), acute bronchitis (43.3 %), and influenza (22.1 %), while those requiring hospitalization were bronchitis and bronchiolitis (8.3 % each one). While active immunoprophylaxis was applied with wide compliance (diphtheria/pertussis/tetanus, 99.5 %; Haemophilus influenzae type b, 72.5 %; pneumococcus, 79.9 %; meningococcus, 77.4 %), only 54 % of children received respiratory syncytial virus (RSV) passive prophylaxis (palivizumab). Of the 35 hospitalizations due to bronchiolitis, 27 (77.1 %) did not receive prophylaxis against RSV, compared with 8 (22.9 %) who received prophylaxis (P < 0.0001). Children with HSCHD are at major risk of respiratory diseases. Passive immunoprophylaxis can help to prevent hospitalizations for bronchiolitis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E (2010) ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 31:2915–2957CrossRefPubMed Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E (2010) ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 31:2915–2957CrossRefPubMed
2.
go back to reference Hoffman JIE, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll Cardiol 39:1890–1900CrossRefPubMed Hoffman JIE, Kaplan S (2002) The incidence of congenital heart disease. J Am Coll Cardiol 39:1890–1900CrossRefPubMed
3.
go back to reference Wren C, Irving CA, Griffiths JA, O’Sullivan JJ, Chaudhari MP, Haynes SR, Smith JH, Hamilton JR, Hasan A (2012) Mortality in infants with cardiovascular malformations. Eur J Pediatr 171:281–287CrossRefPubMed Wren C, Irving CA, Griffiths JA, O’Sullivan JJ, Chaudhari MP, Haynes SR, Smith JH, Hamilton JR, Hasan A (2012) Mortality in infants with cardiovascular malformations. Eur J Pediatr 171:281–287CrossRefPubMed
4.
go back to reference Bjornard K, Riehle-Colarusso T, Gilboa SM, Correa A (2013) Patterns in the prevalence of congenital heart defects, metropolitan Atlanta, 1978–2005. Birt Defects Res A Clin Mol Teratol 97:87–94CrossRef Bjornard K, Riehle-Colarusso T, Gilboa SM, Correa A (2013) Patterns in the prevalence of congenital heart defects, metropolitan Atlanta, 1978–2005. Birt Defects Res A Clin Mol Teratol 97:87–94CrossRef
5.
go back to reference Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A (2008) Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. J Pediatr 153:807–813CrossRefPubMedPubMedCentral Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A (2008) Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. J Pediatr 153:807–813CrossRefPubMedPubMedCentral
6.
go back to reference Wu M-H, Chen H-C, Lu C-W, Wang J-K, Huang S-C, Huang S-K (2010) Prevalence of congenital heart disease at live birth in Taiwan. J Pediatr 156:782–785CrossRefPubMed Wu M-H, Chen H-C, Lu C-W, Wang J-K, Huang S-C, Huang S-K (2010) Prevalence of congenital heart disease at live birth in Taiwan. J Pediatr 156:782–785CrossRefPubMed
7.
go back to reference Delacourt C, Hadchouel A, Toelen J, Rayyan M, de Blic J, Deprest J (2012) Long term respiratory outcomes of congenital diaphragmatic hernia, esophageal atresia, and cardiovascular anomalies. Semin Fetal Neonatal Med 17:105–111CrossRefPubMed Delacourt C, Hadchouel A, Toelen J, Rayyan M, de Blic J, Deprest J (2012) Long term respiratory outcomes of congenital diaphragmatic hernia, esophageal atresia, and cardiovascular anomalies. Semin Fetal Neonatal Med 17:105–111CrossRefPubMed
8.
go back to reference Kussman BD, Geva T, McGowan FX (2004) Cardiovascular causes of airway compression. Paediatr Anaesth 14:60–74CrossRefPubMed Kussman BD, Geva T, McGowan FX (2004) Cardiovascular causes of airway compression. Paediatr Anaesth 14:60–74CrossRefPubMed
9.
go back to reference Massin MM, Astadicko I, Dessy H (2007) Noncardiac comorbidities of congenital heart disease in children. Acta Paediatr 96:753–755CrossRefPubMed Massin MM, Astadicko I, Dessy H (2007) Noncardiac comorbidities of congenital heart disease in children. Acta Paediatr 96:753–755CrossRefPubMed
11.
go back to reference Mathers C, Fat DM, Boerma JT (2008) The global burden of disease: 2004 update. World Health Organization, Geneva, Switzerland vii:146 Mathers C, Fat DM, Boerma JT (2008) The global burden of disease: 2004 update. World Health Organization, Geneva, Switzerland vii:146
12.
go back to reference Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC (2006) Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 24:102–108CrossRefPubMed Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC (2006) Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 24:102–108CrossRefPubMed
13.
go back to reference Sauro A, Barone F, Blasio G, Russo L, Santillo L (2006) Do influenza and acute respiratory infective diseases weigh heavily on general practitioners’ daily practice? Eur J Gen Pract 12:34–36CrossRefPubMed Sauro A, Barone F, Blasio G, Russo L, Santillo L (2006) Do influenza and acute respiratory infective diseases weigh heavily on general practitioners’ daily practice? Eur J Gen Pract 12:34–36CrossRefPubMed
14.
go back to reference Olszewska W, Zambon M, Openshaw PJM (2002) Development of vaccines against common colds. Br Med Bull 62:99–111CrossRefPubMed Olszewska W, Zambon M, Openshaw PJM (2002) Development of vaccines against common colds. Br Med Bull 62:99–111CrossRefPubMed
16.
go back to reference Glezen WP, Paredes A, Taber LH (1980) Influenza in children. Relationship to other respiratory agents. JAMA 243:1345–1349CrossRefPubMed Glezen WP, Paredes A, Taber LH (1980) Influenza in children. Relationship to other respiratory agents. JAMA 243:1345–1349CrossRefPubMed
17.
go back to reference Denny FW, Clyde WA (1986) Acute lower respiratory tract infections in nonhospitalized children. J Pediatr 108(5 pt 1):635–646CrossRefPubMed Denny FW, Clyde WA (1986) Acute lower respiratory tract infections in nonhospitalized children. J Pediatr 108(5 pt 1):635–646CrossRefPubMed
18.
19.
go back to reference Meissner HC (2003) Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 22(2 suppl):S40–S45PubMed Meissner HC (2003) Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 22(2 suppl):S40–S45PubMed
20.
go back to reference Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588–598CrossRefPubMedPubMedCentral Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360:588–598CrossRefPubMedPubMedCentral
21.
go back to reference Cabalka AK (2004) Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 23(1 suppl):S41–S45CrossRefPubMed Cabalka AK (2004) Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 23(1 suppl):S41–S45CrossRefPubMed
22.
go back to reference Lanari M, Giovannini M, Giuffré L, Marini A, Rondini G, Rossi GA, Merolla R, Zuccotti GV, Salvioli GP, Investigators R.A.DA.R. Study Group (2002) Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol 33:458–465CrossRefPubMed Lanari M, Giovannini M, Giuffré L, Marini A, Rondini G, Rossi GA, Merolla R, Zuccotti GV, Salvioli GP, Investigators R.A.DA.R. Study Group (2002) Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol 33:458–465CrossRefPubMed
23.
go back to reference Faldella G, Alessandroni R, Aquilano G, Vandini S, Lanari M, Silvestri M, Pistorio A, Rossi GA (2010) Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab. J Chemother 22:30–35CrossRefPubMed Faldella G, Alessandroni R, Aquilano G, Vandini S, Lanari M, Silvestri M, Pistorio A, Rossi GA (2010) Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab. J Chemother 22:30–35CrossRefPubMed
24.
go back to reference Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T et al (2003) Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from the palivizumab outcomes registry. Pediatr Pulmonol 35:484–489CrossRefPubMed Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T et al (2003) Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from the palivizumab outcomes registry. Pediatr Pulmonol 35:484–489CrossRefPubMed
25.
go back to reference Golombek SG, Berning F, Lagamma EF (2004) Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 23:318–322CrossRefPubMed Golombek SG, Berning F, Lagamma EF (2004) Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J 23:318–322CrossRefPubMed
26.
go back to reference Resch B, Gusenleitner W, Müller WD, Haas J (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 25:120–122CrossRefPubMed Resch B, Gusenleitner W, Müller WD, Haas J (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 25:120–122CrossRefPubMed
27.
go back to reference Adcock PM, Sanders CL, Marshall GS (1998) Standardizing the care of bronchiolitis. Arch Pediatr Adolesc Med 152:739–744CrossRefPubMed Adcock PM, Sanders CL, Marshall GS (1998) Standardizing the care of bronchiolitis. Arch Pediatr Adolesc Med 152:739–744CrossRefPubMed
28.
go back to reference Granbom E, Fernlund E, Sunnegårdh J, Lundell B, Naumburg E (2014) Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease. Acta Paediatr 103:840–845CrossRefPubMed Granbom E, Fernlund E, Sunnegårdh J, Lundell B, Naumburg E (2014) Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease. Acta Paediatr 103:840–845CrossRefPubMed
29.
go back to reference Alexander PMA, Eastaugh L, Royle J, Daley AJ, Shekerdemian LS, Penny DJ (2012) Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease. J Paediatr Child Health 48:395–401CrossRefPubMed Alexander PMA, Eastaugh L, Royle J, Daley AJ, Shekerdemian LS, Penny DJ (2012) Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease. J Paediatr Child Health 48:395–401CrossRefPubMed
30.
go back to reference Andres S, Bauer G, Rodríguez S, Novali L, Micheli D, Fariña D (2012) Hospitalization due to respiratory syncytial virus infection in patients under 2 years of age with hemodynamically significant congenital heart disease. J Pediatr (Rio J) 88:246–252CrossRef Andres S, Bauer G, Rodríguez S, Novali L, Micheli D, Fariña D (2012) Hospitalization due to respiratory syncytial virus infection in patients under 2 years of age with hemodynamically significant congenital heart disease. J Pediatr (Rio J) 88:246–252CrossRef
31.
go back to reference Bollettino della Società Italiana di Cardiologia Pediatrica Anno 13, n. 1 (2006) La Prevenzione Della Malattia Da Virus Respiratorio Sinciziale Nei Bambini Con Cardiopatia Congenita O Acquisita Nell’infanzia. Raccomandazioni della Società Italiana di Cardiologia Pediatrica (SICP) Bollettino della Società Italiana di Cardiologia Pediatrica Anno 13, n. 1 (2006) La Prevenzione Della Malattia Da Virus Respiratorio Sinciziale Nei Bambini Con Cardiopatia Congenita O Acquisita Nell’infanzia. Raccomandazioni della Società Italiana di Cardiologia Pediatrica (SICP)
32.
go back to reference Commissione Cardiopatie Congenite in Età Paediatrica ed Adulta (2009) Cardiopatie congenite in età paediatrica ed adulta. G Ital Cardiol 10(suppl 3–6):58S–59S Commissione Cardiopatie Congenite in Età Paediatrica ed Adulta (2009) Cardiopatie congenite in età paediatrica ed adulta. G Ital Cardiol 10(suppl 3–6):58S–59S
34.
go back to reference Raccomandazioni della Società Italiana di Neonatologia (SIN) per la prevenzione delle malattie da virus respiratorio sinciziale (VRS) Acta Neonatologica Pediatrica 2004, 18:19–30 Raccomandazioni della Società Italiana di Neonatologia (SIN) per la prevenzione delle malattie da virus respiratorio sinciziale (VRS) Acta Neonatologica Pediatrica 2004, 18:19–30
35.
go back to reference Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, for the Palivizumab Outcomes Registry Group (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the palivizumab outcomes registry. J Perinatol 28:511–517CrossRefPubMed Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M, for the Palivizumab Outcomes Registry Group (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the palivizumab outcomes registry. J Perinatol 28:511–517CrossRefPubMed
36.
go back to reference Ozyurt A, Narin N, Baykan A, Argun M, Pamukcu O, Zararsiz G, Sunkak S, Uzum K (2015) Efficacy of palivizumab prophylaxis among infants with congenital heart disease: a case control study. Pediatr Pulmonol 50:1025–1032CrossRefPubMed Ozyurt A, Narin N, Baykan A, Argun M, Pamukcu O, Zararsiz G, Sunkak S, Uzum K (2015) Efficacy of palivizumab prophylaxis among infants with congenital heart disease: a case control study. Pediatr Pulmonol 50:1025–1032CrossRefPubMed
37.
go back to reference Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M (2014) Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther 3:133–158CrossRefPubMedPubMedCentral Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M (2014) Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther 3:133–158CrossRefPubMedPubMedCentral
Metadata
Title
Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study
Authors
Giacomo Pongiglione
Alessandro Possidoni
Umberto di Luzio Paparatti
Anna Maria Costanzo
Giuliana Gualberti
Marco Bonvicini
Alessandro Rimini
Gabriella Agnoletti
Maria Pia Calabrò
Marco Pozzi
Roberto Tumbarello
Patrizia Salice
Patrizio Fiorini
Maria Giovanna Russo
Ornella Milanesi
Publication date
01-12-2016
Publisher
Springer US
Published in
Pediatric Cardiology / Issue 8/2016
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-016-1473-9

Other articles of this Issue 8/2016

Pediatric Cardiology 8/2016 Go to the issue